Author(s): Satish Balkrishna Bhise, Sevukarajan Mookkan

Email(s): msevukan@rediffmail.com

DOI: Not Available

Address: Satish Balkrishna Bhise* and Sevukarajan Mookkan
Department of Biopharmaceutics, Government College of pharmacy, Karad-415124(M.S). India.
* Corresponding Author

Published In:   Volume - 1,      Issue - 3,     Year - 2008


ABSTRACT:
The use of Fixed dose combinations (FDCs) of antitubercular drugs in the short course chemotherapy of tuberculosis is being promoted internationally. However poor bioavailability of rifampicin has been perceived as a major bottleneck in successful treatment of tuberculosis. It perhaps is amongst one of the contributory factor which may lead to increasing resistance to anti-tubercular drugs. The present article critically focuses on various probable physical and/or chemical reasons responsible for poor/variable bioavailability of rifampicin in FDC and suggests the various approaches which may be successfully employed to overcome the aforementioned problems associated with rifampicin in FDCs.


Cite this article:
Satish Balkrishna Bhise, Sevukarajan Mookkan. Poor Bioavailability of Rifampicin- A Global Emergency. Research J. Pharm. and Tech. 1(3): July-Sept. 2008; Page 155-160.

Cite(Electronic):
Satish Balkrishna Bhise, Sevukarajan Mookkan. Poor Bioavailability of Rifampicin- A Global Emergency. Research J. Pharm. and Tech. 1(3): July-Sept. 2008; Page 155-160.   Available on: https://rjptonline.org/AbstractView.aspx?PID=2008-1-3-43


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available